Novo Gains After Doctors Find Heart Risk Drops on Wegovy

Patients who took the diet drug Wegovy for a year had a reduced risk of heart disease, a promising finding that sent Novo Nordisk A/Sshares to a record.

The stock rose as much as 3.1% in Copenhagen in response to study results presented over the weekend. Wegovy’s prodigious success has turned Novo into Europe’s second-most valuable firm behind the luxury group LVMH.

Read More: Obesity Drug Hit Makes Novo More Valuable Than Nestle

People followed in the Wegovy trial presented at the European Congress on Obesity saw their 10-year risk of cardiovascular disease decline by 18%, said Andres Acosta ...